Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24673393 | 0.87 | KMT2A (0.50) | KMT2AMEN1USP2CYP2C19ALDH1A1 | |
| SCHEMBL24509122 | 0.87 | KMT2A (0.50) | KMT2AMEN1USP2CYP2C19ALDH1A1 | |
| SCHEMBL23568546 | 0.86 | KMT2A (0.47) | KMT2AMEN1USP2CYP2C19ALDH1A1 | |
| SCHEMBL22861745 | 0.83 | MEN1 (0.40) | KMT2AMEN1USP2CYP2C19ALDH1A1 | |
| SCHEMBL17853874 | 0.82 | KMT2A (0.66) | KMT2AMEN1USP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL25123160 | 0.81 | MEN1 (0.49) | KMT2AMEN1USP2CYP2C19ALDH1A1 | |
| SCHEMBL22909028 | 0.80 | PAOX (0.44) | KMT2AMEN1ALDH1A1KDM4EPOLB | |
| SCHEMBL24572502 | 0.80 | PAOX (0.44) | KMT2AMEN1ALDH1A1KDM4EPOLB | |
| SCHEMBL23568038 | 0.79 | MEN1 (0.46) | KMT2AMEN1USP2CYP2C19ALDH1A1 | |
| SCHEMBL24572498 | 0.78 | PAOX (0.45) | KMT2AMEN1ALDH1A1TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KMT2A 445/4885MEN1 4055/4885USP2 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.